Unknown

Dataset Information

0

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.


ABSTRACT: PURPOSE OF REVIEW:In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy. RECENT FINDINGS:Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (tisagenlecleucel), a CD19 CAR T cell product developed by Novartis and the University of Pennsylvania, was recently approved for clinical use by the Food and Drug Administration, representing a landmark in the application of adoptive T cell therapies. As CART19 enters routine clinical use, improving the efficacy of this exciting platform is the next step in broader application. Novel gene-editing technologies like CRISPR-Cas9 allow facile editing of specific genes within the genome, generating a powerful platform to further optimize the activity of engineered T cells.

SUBMITTER: Singh N 

PROVIDER: S-EPMC5709224 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer.

Singh Nathan N   Shi Junwei J   June Carl H CH   Ruella Marco M  

Current hematologic malignancy reports 20171201 6


<h4>Purpose of review</h4>In this review, we discuss the most recent developments in gene-editing technology and discuss their application to adoptive T cell immunotherapy.<h4>Recent findings</h4>Engineered T cell therapies targeting cancer antigens have demonstrated significant efficacy in specific patient populations. Most impressively, CD19-directed chimeric antigen receptor T cells (CART19) have led to impressive responses in patients with B-cell leukemia and lymphoma. CTL019, or KYMRIAH™ (t  ...[more]

Similar Datasets

| S-EPMC8099660 | biostudies-literature
| S-EPMC4786923 | biostudies-other
| S-EPMC8193798 | biostudies-literature
| S-EPMC6292222 | biostudies-literature
| S-EPMC1131930 | biostudies-literature
| S-EPMC5684446 | biostudies-literature
| S-EPMC5131771 | biostudies-literature
| S-EPMC7612108 | biostudies-literature
| S-EPMC4869278 | biostudies-literature
| S-EPMC8714942 | biostudies-literature